TheraRadar
Data updated: May 26, 2026

JETREA (ocriplasmin)

Trial Activity: Declining
Ophthalmology Approved 2012-10-17
Jump to: Indications Approvals Trials Competitors Safety Patents

Development Insights

ThromboGenics conducting 8 trials (80%)
7 indications explored (Moderate)
→ vitrectomy (6 trials)
→ vitreomacular traction (1 trials)
→ vitreomacular adhesion (1 trials)
2
Indications
--
Phase 3 Trials
2
Priority Reviews
13
Years on Market

Details

Status
Prescription
First Approved
2012-10-17
Routes
INTRAVITREAL
Dosage Forms
INJECTABLE

Companies

THROMBOGENICS, INC
Active Ingredient: OCRIPLASMIN

JETREA Approval History

2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Original
New Indication
New Form
Label Update
4 FDA actions from 2012 to 2017 · 1 indication expansions
Feb 2017 SUPPL
Label · Labeling
FDA Letter Label
Mar 2016 SUPPL
Label · Labeling
FDA Letter Label
Jun 2014 SUPPL Priority
Efficacy
FDA Letter Label

What JETREA Treats

2 FDA approvals

Originally approved for its first indication in 2012 . Covers 2 distinct patient populations.

  • Other (2)
📋

Clinical Trial Registry

6 trials
Trial Sponsor ID Phase Status Title
NCT02035748 results posted M-13-056 2013-005464-25 Ph 4 completed Assessment of Patients Treated With JETREA® for Vitreomacular Traction
NCT01429441 OASIS results posted TG-MV-014 Ph 3 completed Ocriplasmin for Treatment for Symptomatic Vitreomacular Adhesion Including Macular Hole
NCT01889251 results posted J-12-075 Ph 3 completed A Phase III Study of A01016 in Subjects With Symptomatic Vitreomacular Adhesion
NCT00986362 MIC results posted TG-MV-009 Ph 2 completed Clinical Trial of Intravitreal Microplasmin in Infants and Children Scheduled for Vitrectomy
NCT00913744 MIVI-5 results posted TG-MV-005 Ph 2 completed Safety and Efficacy Study of Intravitreal Ocriplasmin in Subjects With AMD With Focal Vitreomacular Adhesion
NCT01159665 MIVI-10 results posted TG-MV-010 Ph 2 completed The Purpose of This Study is to Evaluate the Pharmacokinetic Properties of Intravitreal Ocriplasmin Prior to Planned Primary Pars Plana Vitrectomy (PPV)
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...
⭐

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

ClinicalTrials.gov ↗ Pro

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

JETREA FDA Label Details

Track JETREA with TheraRadar Pro

Watchlist alerts, full database access, CSV exports across 14,000+ drugs.

Upgrade to Pro

Data Sources

FDA Approval: BLA125422 → Trials: ClinicalTrials.gov →

Data sourced from official FDA and NIH databases. Click links to verify on original sources.

How We Calculate These Metrics

Trial Activity Stage

Measures the current development activity pattern based on trial phases, status, and trends. Important: This measures R&D activity, not commercial lifecycle.

Trial statuses: "Active" means recruiting or ongoing. "Completed" means reached planned endpoint. "Terminated" means stopped early—often due to safety, efficacy, or business reasons.

  • Growth: High proportion of early-phase trials (Phase 1/2), active development
  • Expansion: Significant Phase 3 activity, approaching or pursuing approvals
  • Mature: Substantial Phase 4 post-marketing studies
  • Stable: Mixed phase distribution, steady development
  • Declining: Low active trial ratio, reduced R&D investment